INS and Insulin resistance: Significant improvements in Homeostatic Model Assessment for Insulin Resistance (HOMA2-IR) computed with fasting insulin were observed with retatrutide doses of 4 mg or greater, with changes up to −69.3% at 48 weeks (P < 0.001 versus placebo).